Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 22.77 USD -14.04% Market Closed
Market Cap: 324.9m USD

EV/EBITDA
Enterprise Value to EBITDA

-0.6
Current
0.5
Median
6.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.6
=
Enterprise Value
50.4m USD
/
EBITDA
-79.4m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Neurogene Inc
NASDAQ:NGNE
Average EV/EBITDA: 23.1
Negative Multiple: -0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 240 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.6
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
9%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -460.8 N/A N/A
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
63.2
769%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A